ORIC Pharmaceuticals (NASDAQ:ORIC) Earns Overweight Rating from Cantor Fitzgerald
Cantor Fitzgerald reiterated their overweight rating on shares of ORIC Pharmaceuticals (NASDAQ:ORIC – Free Report) in a research note released on Monday, Benzinga reports. Cantor Fitzgerald also issued estimates for ORIC Pharmaceuticals’ FY2024 earnings at ($1.82) EPS. Several other research analysts have also commented on the company. Wedbush reaffirmed an outperform rating and set a […]
More Stories
Air Transat Pilots Issue Strike Notice, Causing Flight Suspensions
By Olivia Gomm The union representing Air Transat pilots has issued a 72-hour strike notice, saying that the pilots intend...
Dollar General Plans to Open 450 New Stores in US in 2026
By Rob Sabo Backed by strong third-quarter net sales of $10.6 billion, Dollar General on Dec. 4 said it plans...
Dr. Oz Threatens to Pull Funding From Minnesota After $1 Billion in Medicaid Funding Was Stolen by Fraudsters
By Jacki Thrapp The Centers for Medicare & Medicaid Services (CMS) threatened to withhold federal funding from Minnesota after fraudsters...
FBI Director Patel Provides Update on Charlie Kirk Assassination Investigation
By Jack Phillips FBI Director Kash Patel has provided an update on the investigation of the assassination of Charlie Kirk,...
Watchdog Uncovers Massive Fraud, Waste in Obamacare Insurance Tax Credits
By Naveen Athrappully An analysis of the Patient Protection and Affordable Care Act (PPACA), commonly known as Obamacare, has unveiled...
US Investor Home Purchases Stall in 3rd Quarter Amid Falling Flipping, Rental Profits
By Mary Prenon Investor home purchases saw little advancement in the third quarter of this year, with just a 1...